1-arylsulfonyl-3-substituted indole and indoline derivatives useful in the treatment of central nervous system disorders

1. A 1-arylsulfonyl-3-substituted indole or indoline compound having the general formula I

wherein

Ar is selected from phenyl, biphenyl, naphthyl, thienyl, furyl, benzothienyl, benzothiadiazolyl, 2,3-dihydrobenzofuranyl, 2,3-dihydrobenzodioxinyl, quinolinyl, and isoquinolinyl, Ar being optionally substituted with 1-5 substitutents selected from halogen, (C 1-4 )alkyl (optionally substituted with halogen), (C 1-4 )alkyloxy (optionally substituted with halogen), (C 6-12 )aryl (optionally substituted with halogen or (C 1-4 )alkyloxy), (C 6-12 )aryloxy (optionally substituted with halogen), di(C 1-4 )alkylamino, (C 1-4 )alkanoyl or (C 1-4 )alkanoylamino;

the dotted line represents an optional bond;

n is 0 or 1;

m is 2-3;

R 6 represents 1-4 substituents independently selected from H, (C 1-4 )alkyl (optionally substituted with halogen), (C 1-4 )alkyloxy (optionally substituted with halogen), (C 1-4 )alkyloxycarbonyl, cyano, nitro and halogen;

R 7 together with R 9 complete a 7-membered saturated ring;

each R 8 is independently H, (C 1-4 ) alkyl or (C 6-12 )aryl (optionally substituted with halogen, (C 1-4 )alkyl or (C 1-4 )alkyloxy);

and

R 10 is H, (C 1-4 )alkyl, (C 6-12 )aryl or (C 6-12 )aryl(C 1-4 )alkyl;

each R 11 is independently H or (C 1-4 )alkyl; or

a pharmaceutically acceptable salt thereof.

2. The 1-arylsulfonyl-3-substituted indole or indoline compound of claim 1 , wherein the Ar is selected from phenyl, naphthyl, thienyl and benzothienyl.

3. The 1-arylsulfonyl-3-substituted indole or indoline derivative of claim 1 , wherein m is 2, all of R 8 and R 11 are H, R 10 is H or (C 1-4 )alkyl.

4. The 1-arylsulfonyl-3-substituted indole or indoline compound of claim 1 , wherein n is 0.

5. A pharmaceutical composition, comprising:

the 1-arylsulfonyl-3-substituted indole or indoline compound of formula I or a pharmaceutically acceptable salt thereof, as according to claim 1 and

a pharmaceutically acceptable carrier therefore.

6. A method of treating a disorder selected from psychosis, schizophrenia, manic depressions, depressions, neurological disorders, cognitive enhancement, Parkinson's disease, amyotrophic lateral sclerosis, Alzheimer's disease or Huntington's disease, in a patient in need thereof comprising administering to the patient an effective amount of a 1-arylsulfonyl-3-substituted indole or indoline compound of claim 1 .